Zhaomu Zeng

Zhaomu Zeng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2022 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZZZhaomu Zeng
Zhaomu Zeng
YCYueyue Chen
Yueyue Chen
XGXiuchao Geng
Xiuchao Geng
YZYuhao Zhang
Yuhao Zhang
XWXichao Wen
Xichao Wen
ZSZhiwei Sun
Zhiwei Sun
As the most common primary tumour of the central nervous system, gliomas have a high recurrence rate after surgical resection and are resistant to chemotherapy, particularly high‑grade gliomas dominated by glioblastoma multiforme (GBM). The prognosis of GBM remains poor despite improvements in treatment modalities, posing a serious threat to human health. At present, although drugs such as temozolomide, cisplatin and bevacizumab, are effective in improving the overall survival of patients with GBM, most patients eventually develop drug resistance, leading to poor clinical prognosis. The development of multidrug resistance has therefore become a major obstacle to improving the effectiveness of chemotherapy for GBM. The ability to fully understand the underlying mechanisms of chemotherapy resistance and to develop novel therapeutic targets to overcome resistance is critical to improving the prognosis of patients with GBM. Of note, growing evidence indicates that a large number of abnormally expressed noncoding RNAs (ncRNAs) have a central role in glioma chemoresistance and may target various mechanisms to modulate chemosensitivity. In the present review, the roles and molecular mechanisms of ncRNAs in glioma drug resistance were systematically summarized, the potential of ncRNAs as drug resistance markers and novel therapeutic targets of glioma were discussed and prospects for glioma treatment were outlined. ncRNAs are a research direction for tumor drug resistance mechanisms and targeted therapies, which not only provides novel perspectives for reversing glioma drug resistance but may also promote the development of precision medicine for clinical diagnosis and treatment.

5 June 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CXCan Xu
Can Xu
JYJin Yang
Jin Yang
HXHuan Xiong
Huan Xiong
XCXiaoteng Cui
Xiaoteng Cui
YZYuhao Zhang
Yuhao Zhang
RXRuxiang Xu
Ruxiang Xu
Glioblastoma (GBM) is classified into subtypes according to the molecular expression profile; the proneural subtype has a relatively good prognosis, and the mesenchymal type is the most aggressive form with the worst prognosis. GBM undergoes proneural–mesenchymal transition (PMT) during its evolution or in response to changes in the microenvironment or therapeutic interventions. PMT is accompanied by infiltration of non-tumor cells, decreased tumor purity, and immune evasion. However, the cellular and molecular mechanisms underlying PMT remain unclear. Differentially expressed genes (DEGs) were identified using GBM transcriptome datasets, and prognostic analysis was performed to screen for PMT-related genes (PMTRGs). Consensus cluster analysis was followed by Gene Set Enrichment Analysis, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes analyses of DEGs to determine the biological functions and pathways regulated by PMTRGs. CIBERSORT, TIMER, MCPCOUNTER, and XCELL algorithms were used to analyze immune cell infiltration patterns. The TIDE algorithm was used to examine immunotherapy scores. The Lasso, Cox, and Step machine learning algorithms were used to construct and screen the optimal risk assessment prognostic model. PMTRG expression patterns in patient tissues and different cell subsets were examined by proteomics and single-cell transcriptome data analysis. Seventeen DEGs and prognostic PMTRGs were identified in proneural and mesenchymal subtypes. PMTRG-related mRNA interactions and protein–protein interaction networks were associated with the immune activity of GBM. Consensus cluster analysis based on PMTRGs divided GBM into three independent subclusters. Functional and pathway analyses showed that PMTRGs were highly expressed in the C1 subcluster, which was associated with GBM mesenchymal isoforms, pathways, and poor prognosis, and showed stronger immune responses. Four immune evaluation algorithms and TIDE analysis showed that the C1 cluster had high levels of immune cell infiltration and immune molecule scores. The prognostic risk assessment model based on PMTRGs can effectively predict the prognosis of GBM patients. Proteomic data from immunohistochemistry and single-cell transcriptome data suggested that PMTRGs are predominantly expressed in monocytes, macrophages, and blood vessels rather than in tumor cells. This study identified 17 key genes associated with PMT in GBM. These PMTRGs are mainly expressed on immune cells and blood vessels in the GBM microenvironment and are associated with poor prognosis, suggesting that PMT events mainly arise from the infiltration and activation of immune cells derived from the bone marrow and blood vessels. These findings provide new evidence and targets for the treatment of GBM.

26 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
FBFengxia Bai
Fengxia Bai
LHLongchao Han
Longchao Han
JYJifeng Yang
Jifeng Yang
YLYuxiu Liu
Yuxiu Liu
XLXiangmeng Li
Xiangmeng Li
HZHaisong Zhang
Haisong Zhang
Purpose: The pathogenesis of renal fibrosis (RF) involves intricate interactions between profibrotic processes and immune responses. This study aimed to explore the potential involvement of the pyroptosis signaling pathway in immune microenvironment regulation within the context of RF. Through comprehensive bioinformatics analysis and experimental validation, we investigated the influence of pyroptosis on the immune landscape in RF.Methods: We obtained RNA-seq datasets from Gene Expression Omnibus (GEO) databases and identified Pyroptosis-Associated Regulators (PARs) through literature reviews. Systematic evaluation of alterations in 27 PARs was performed in RF and normal kidney samples, followed by relevant functional analyses. Unsupervised cluster analysis revealed distinct pyroptosis modification patterns. Using single-sample gene set enrichment analysis (ssGSEA), we examined the correlation between pyroptosis and immune infiltration. Hub regulators were identified via weighted gene coexpression network analysis (WGCNA) and further validated in a single-cell RNA-seq dataset. We also established a unilateral ureteral obstruction-induced RF mouse model to verify the expression of key regulators at the mRNA and protein levels.Results: Our comprehensive analysis revealed altered expression of 19 PARs in RF samples compared to normal samples. Five hub regulators, namely PYCARD, CASP1, AIM2, NOD2, and CASP9, exhibited potential as biomarkers for RF. Based on these regulators, a classifier capable of distinguishing normal samples from RF samples was developed. Furthermore, we identified correlations between immune features and PARs expression, with PYCARD positively associated with regulatory T cells abundance in fibrotic tissues. Unsupervised clustering of RF samples yielded two distinct subtypes (Subtype A and Subtype B), with Subtype B characterized by active immune responses against RF. Subsequent WGCNA analysis identified PYCARD, CASP1, and NOD2 as hub PARs in the pyroptosis modification patterns. Single-cell level validation confirmed PYCARD expression in myofibroblasts, implicating its significance in the stress response of myofibroblasts to injury. In vivo experimental validation further demonstrated elevated PYCARD expression in RF, accompanied by infiltration of Foxp3+ regulatory T cells.Conclusions: Our findings suggest that pyroptosis plays a pivotal role in orchestrating the immune microenvironment of RF. This study provides valuable insights into the pathogenesis of RF and highlights potential targets for future therapeutic interventions.

1 January 2024 in American Journal of Translational Research
Verified
Journal Article
Closed access
LGLianting Geng
Lianting Geng
ZBZetong Bai
Zetong Bai
XWXichao Wen
Xichao Wen
HLHaipeng Liu
Haipeng Liu
HXHaipeng Xie
Haipeng Xie
KZKebin Zheng
Kebin Zheng
Objectives: PTEN-Long is a translational variant of phosphatase and tensin homolog (PTEN). This study aimed to assess the effect of PTEN-Long on the biological characteristics of glioma cells and related mechanisms. Methods: A vector stably expressing PTEN-Long was established and transfected into cells, serving as the overexpression group, while a set of empty vectors served as the negative control group. Real-time reverse transcription-polymerase chain reaction (RT-PCR) and western blot were used to detect the expression of PTEN-Long and phosphatidylinositol 3-kinase, Protein kinase B, andnuclear factor-κB (PI3K-AKT-NF-κB). Cell proliferation was assessed with the Cell Counting Kit 8 (CCK8) assay, migration through the scratch test, and invasion by the transwell chamber assay. Cell cycle analysis was performed using flow cytometry. The volume and weight of subcutaneous tumors in nude mice were also evaluated. Results: PTEN-Long expression led to downregulation of p-Akt, NF-κB p65, p-NF-κB p65, and Bcl-xl, and up-regulation of IκBα. In addition, it inhibited glioma cell proliferation, induced cell cycle arrest in the G0/G1 phase, and reduced cell migration and invasion. Moreover, PTEN-Long inhibited the growth of subcutaneous glioma in nude mice. Conclusions: PTEN-Long inhibits the proliferation, migration, and invasion and induces apoptosis in glioma cells by inhibiting PI3K-AKT-NF-κb signaling, implying that PTEN-Long may be a new target for glioma treatment.

15 April 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
LZLiangchen Zhong
Liangchen Zhong
ZLZhenyu Luo
Zhenyu Luo
DWDengfeng Wan
Dengfeng Wan
ZZZhaomu Zeng
Zhaomu Zeng
JZJianzhong Zhang
Jianzhong Zhang
Introduction: This study was performed to evaluate the surgical efficiency, localization accuracy, biopsy success rate, and operative safety of three-dimensional (3D) structured-light robot-assisted stereotactic brain biopsy using the Huake Precision SR1-3D system. Methods: Clinical data were retrospectively collected from 54 patients who underwent stereotactic brain biopsy in the Department of Neurosurgery, at Jiangxi Provincial People’s Hospital between February 2017 and November 2022. Among them, 27 patients underwent frame-based stereotactic brain biopsy using the Anke system, and 27 patients underwent robotic-assisted frame-less stereotactic brain biopsy using the Huake Precision SR1-3D structured-light robot. The registration error of the Sinovation software based 3D structured-light facial scan was assessed. Operative time, diagnostic yield, incidence of adverse surgical events, length of hospital stay, surgical costs, entry-point error, and target-point error were compared between the two groups. Results: A total of 54 patients were analyzed, including 27 in the robot-assisted group and 27 in the frame-based group. The mean registration error of the 3D structured-light facial scan was 0.31 ± 0.07 mm. The mean operative time in the robot-assisted group was significantly shorter than that in the frame-based group ( p < 0.05). No significant differences were observed in diagnostic yield, postoperative adverse event rate, or length of hospital stay between the groups (all p > 0.05). The surgical costs were higher in the robot-assisted group than in the frame-based group ( p < 0.05). The robot-assisted group exhibited smaller entry-point and target-point errors compared to the frame-based group (both p < 0.05). Conclusion: This study found that, 3D structured-light robot-assisted stereotactic brain biopsy is associated with shorter operative times and reduced localization error compared to frame-based stereotactic brain biopsy, demonstrating favorable precision and procedural efficiency.

15 June 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HFHongan Fei
Hongan Fei
XWXichao Wen
Xichao Wen
WWWensong Wu
Wensong Wu
HLHaiPeng Liu
HaiPeng Liu
HXHaipeng Xie
Haipeng Xie
ZBZetong Bai
Zetong Bai
Glioblastoma (GBM) is one of the most aggressive brain tumors, and its immunotherapy faces significant challenges, including the physical barrier of the blood-brain barrier, the tumor immunosuppressive microenvironment, and the difficulty of effective immune cell infiltration into tumor tissue. In recent years, the anatomical and functional basis of the meningeal immune system has been gradually revealed, particularly the discovery of the dural lymphatic system and tissue-resident border-associated macrophages (rBAMs), providing new insights for GBM immunotherapy. “Interstitial” immunotherapy, as an innovative strategy, emphasizes a shift from the traditional focus on the tumor interior to the tumor “border,” leveraging the unique advantages of the meningeal immune system to enhance the effectiveness of immune responses. This review systematically examines the current status and dilemmas of GBM immunotherapy, the anatomical and functional basis of meningeal immunity, the discovery and mechanisms of rBAMs, the theoretical implications of “interstitial” immunotherapy, and the clinical translation prospects and challenges of this strategy, aiming to provide new theoretical support and practical guidance for GBM immunotherapy.